These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 26383153)
1. Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors. Sharma R; Kallur KG; Ryu JS; Parameswaran RV; Lindman H; Avril N; Gleeson FV; Lee JD; Lee KH; O'Doherty MJ; Groves AM; Miller MP; Somer EJ; Coombes CR; Aboagye EO J Nucl Med; 2015 Dec; 56(12):1855-61. PubMed ID: 26383153 [TBL] [Abstract][Full Text] [Related]
2. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent. Battle MR; Goggi JL; Allen L; Barnett J; Morrison MS J Nucl Med; 2011 Mar; 52(3):424-30. PubMed ID: 21321268 [TBL] [Abstract][Full Text] [Related]
3. [¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrins. Mena E; Owenius R; Turkbey B; Sherry R; Bratslavsky G; Macholl S; Miller MP; Somer EJ; Lindenberg L; Adler S; Shih J; Choyke P; Kurdziel K Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1879-88. PubMed ID: 24973039 [TBL] [Abstract][Full Text] [Related]
4. In vivo alpha-V beta-3 integrin expression in human aortic atherosclerosis. Jenkins WS; Vesey AT; Vickers A; Neale A; Moles C; Connell M; Joshi NV; Lucatelli C; Fletcher AM; Spratt JC; Mirsadraee S; van Beek EJ; Rudd JH; Newby DE; Dweck MR Heart; 2019 Dec; 105(24):1868-1875. PubMed ID: 31422361 [TBL] [Abstract][Full Text] [Related]
5. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients. Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020 [TBL] [Abstract][Full Text] [Related]
6. Test-Retest Variability in Lesion SUV and Lesion SUR in Hofheinz F; Apostolova I; Oehme L; Kotzerke J; van den Hoff J J Nucl Med; 2017 Nov; 58(11):1770-1775. PubMed ID: 28473598 [TBL] [Abstract][Full Text] [Related]
7. [ Sharma R; Valls PO; Inglese M; Dubash S; Chen M; Gabra H; Montes A; Challapalli A; Arshad M; Tharakan G; Chambers E; Cole T; Lozano-Kuehne JP; Barwick TD; Aboagye EO Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1239-1251. PubMed ID: 31754793 [TBL] [Abstract][Full Text] [Related]
9. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system. Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008 [TBL] [Abstract][Full Text] [Related]
10. Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [(18)F]fluciclatide kinetics and [ (15)O]H 2O PET. Kenny LM; Tomasi G; Turkheimer F; Larkin J; Gore M; Brock CS; Mangar S; Aboagye EO EJNMMI Res; 2014 Dec; 4(1):30. PubMed ID: 26055935 [TBL] [Abstract][Full Text] [Related]
11. Test-Retest Reproducibility of Kurland BF; Peterson LM; Shields AT; Lee JH; Byrd DW; Novakova-Jiresova A; Muzi M; Specht JM; Mankoff DA; Linden HM; Kinahan PE J Nucl Med; 2019 May; 60(5):608-614. PubMed ID: 30361381 [TBL] [Abstract][Full Text] [Related]
12. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. Kurland BF; Muzi M; Peterson LM; Doot RK; Wangerin KA; Mankoff DA; Linden HM; Kinahan PE J Nucl Med; 2016 Feb; 57(2):226-30. PubMed ID: 26493206 [TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
14. Reproducibility and Repeatability of Semiquantitative Vargas HA; Kramer GM; Scott AM; Weickhardt A; Meier AA; Parada N; Beattie BJ; Humm JL; Staton KD; Zanzonico PB; Lyashchenko SK; Lewis JS; Yaqub M; Sosa RE; van den Eertwegh AJ; Davis ID; Ackermann U; Pathmaraj K; Schuit RC; Windhorst AD; Chua S; Weber WA; Larson SM; Scher HI; Lammertsma AA; Hoekstra OS; Morris MJ J Nucl Med; 2018 Oct; 59(10):1516-1523. PubMed ID: 29626121 [No Abstract] [Full Text] [Related]
19. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies. Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582 [TBL] [Abstract][Full Text] [Related]
20. PET of αvbeta3-integrin and αvbeta5-integrin expression with 18F-fluciclatide for assessment of response to targeted therapy: ready for prime time? Beer AJ; Schwaiger M J Nucl Med; 2011 Mar; 52(3):335-7. PubMed ID: 21321266 [No Abstract] [Full Text] [Related] [Next] [New Search]